文献速递血栓与止血

两例遗传性蛋白C缺陷症导致静脉血栓的分子致病机制分析

[Analysis of two cases of hereditary protein C deficiency causing venous thrombosis].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2025-01-01

对两名因静脉血栓栓塞症就诊的先证者及其家系进行蛋白C活性、抗原检测、基因测序和体外表达实验,发现PROC基因第9外显子杂合错义突变p.Leu278Pro和p.Trp444Arg导致蛋白C分泌障碍,可能是遗传性蛋白C缺陷症的分子致病机制。

要点

  • 两例先证者PC∶A分别为35%和40%,PC∶Ag分别为44%和39%,D-二聚体分别升高至4.42 mg/L和0.83 mg/L。
  • PROC基因第9外显子杂合错义突变p.Leu278Pro和p.Trp444Arg均为有害突变,导致蛋白结构改变。
  • 体外表达显示两种突变mRNA水平无显著差异,但细胞培养上清液PC∶Ag和蛋白表达量低于野生型,裂解液中高于野生型。

核心结论

  • PROC基因第9外显子杂合错义突变p.Leu278Pro和p.Trp444Arg导致PC蛋白分泌障碍可能是遗传性PC缺陷症的分子致病机制。

研究设计与样本

  • 对两名静脉血栓栓塞症先证者及家系成员进行临床资料和血样本采集,检测PC∶A、PC∶Ag及其他凝血指标。
  • 采用凝血酶生成试验评估抗凝能力,DNA直接测序确定PROC基因突变位点,生物信息学软件分析保守性和致病性,PyMOL分析蛋白质三维模型。
  • 构建野生型和两个突变型表达载体,瞬时转染HEK293T细胞,提取阳性转染细胞总RNA研究转录水平。
  • 采用ELISA法、Western blot和细胞免疫荧光实验研究PC突变蛋白翻译水平。

主要发现

  • 先证者1和2的PC∶A分别为35%和40%,PC∶Ag分别为44%和39%,D-二聚体分别升高至4.42 mg/L和0.83 mg/L,其他相关凝血指标无明显异常。
  • 测序显示先证者1存在PROC基因第9外显子c.833T>C(p.Leu278Pro)杂合错义突变,先证者2存在c.1330T>C(p.Trp444Arg)杂合错义突变。
  • 凝血酶生成试验表明两位先证者及其携带PROC基因突变的家系成员抗凝功能均受损。
  • 保守性分析显示Leu278和Trp444在同源物种间呈高度保守,致病性分析显示p.Leu278Pro和p.Trp444Arg均为有害突变。
  • 体外表达实验显示两种突变mRNA表达水平与野生型无明显差异,但细胞培养上清液PC∶Ag含量和PC蛋白表达量明显低于野生型,细胞培养裂解液中高于野生型。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the molecular pathogenic mechanism of venous thrombosis caused by heterozygous missense mutations in two protein C (PROC) genes through laboratory phenotype analysis, genetic mutation analysis, and in vitro expression experiments. Methods: Two probands presented with venous thromboembolism at the First Affiliated Hospital of Wenzhou Medical University. Clinical data and blood samples were collected from the probands and their family members to evaluate the plasma protein C (PC) activity (PC∶A), PC antigen (PC∶Ag) levels, and other relevant coagulation parameters. The anticoagulant capacity was assessed using the thrombin generation test (TGT). The mutation sites of the PROC gene were identified using direct DNA sequencing. Bioinformatics software was used to analyze the conservation and pathogenicity of the mutated gene. PyMOL software was used for the analysis of the protein three-dimensional models and interactions between mutated amino acids. Wild-type and two mutant expression vectors were constructed and HEK293T cells were transiently transfected. Total cellular RNA was extracted from positively transfected cells to investigate the transcriptional levels of the mutant PROC gene. Enzyme-linked immunosorbent assay, Western blot, and cellular immunofluorescence assays were used to investigate the translation levels of the mutant PROC protein. Results: Probands 1 and 2 exhibited PC∶A levels of 35% and 40% and PC∶Ag levels of 44% and 39%, with increasing D-dimer levels to 4.42 mg/L and 0.83 mg/L, respectively. Meanwhile, other coagulation parameters revealed no significant abnormalities. TGT demonstrated impaired anticoagulant function in both proband witnesses and their familial PC carriers. Sequencing analysis revealed heterozygous missense mutations c. 833T>C (p. Leu278Pro) in proband 1 and c. 1330T>C (p. Trp444Arg) in proband 2 within exon 9 of the PROC gene. Conservation analysis revealed that Leu278 and Trp444 were highly conserved across homologous species. Pathogenicity analysis indicated that both p. Leu278Pro and p. Trp444Arg mutations are deleterious. Protein modeling analysis demonstrated that both mutations induce structural alterations in the protein. In vitro expression experiments revealed that compared with the wild-type, both p. Leu278Pro and p. Trp444Arg mutations showed no significant differences in the mRNA expression level of the PC protein. However, both mutations caused significantly lower PC∶Ag content and protein expression levels in the cell culture supernatant compared with the wild-type, whereas higher levels were observed in the cell culture lysate. This indicates the association of both mutations with the secretion function of the PC protein. Conclusion: The heterozygous missense mutations p. Leu278Pro and p. Trp444Arg in exon 9 of the PROC gene in both probands are associated with decreased PC levels. 目的: 探究两个遗传性蛋白C(PC)缺陷症家系的分子致病机制。 方法: 两位先证者均因静脉血栓栓塞症(VTE)分别于2021年6月和2022年10月就诊于温州医科大学附属第一医院,收集先证者和家系成员临床资料及血样本,检测血浆蛋白C活性(PC∶A)和抗原(PC∶Ag)含量及其他相关凝血指标。以凝血酶生成试验(TGT)评估其抗凝能力。采用DNA直接测序法确定PROC基因突变位点。用生物信息学软件分析突变基因的保守性和致病性。用PyMOL软件分析蛋白质三维模型以及突变氨基酸之间的相互作用。构建野生型和两个突变型表达载体,并瞬时转染HEK293T细胞,提取阳性转染细胞内的细胞总RNA进行突变PROC基因转录水平的研究。采用ELISA法和Western blot和细胞免疫荧光实验进行PC突变蛋白翻译水平的研究。 结果: 家系1、2先证者的PC∶A分别降至35%、40%,PC∶Ag分别降至44%、39%,D-二聚体分别升高至4.42 mg/L、0.83 mg/L,其他相关凝血指标无明显异常。测序分析显示,家系1、2先证者的PROC基因第9外显子分别存在c.833T>C(p.Leu278Pro)、c.1330T>C(p.Trp444Arg)杂合错义突变。凝血酶生成试验表明两位先证者及其携带以上PROC基因突变家系成员的抗凝功能均受损。保守性分析显示Leu2278和Trp444在同源物种间呈高度保守。致病性分析显示p.Leu278Pro和p.Trp444Arg均为有害突变。蛋白质模型分析显示该两种突变均能导致蛋白质结构发生改变。体外表达实验显示,与野生型相比,p.Leu278Pro和p.Trp444Arg两种突变在mRNA表达层面没有明显差异,但两种突变导致细胞培养上清液PC∶Ag含量和PC蛋白表达量明显低于野生型,而在细胞培养裂解液中高于野生型。 结论: PROC基因第9外显子杂合错义突变p.Leu278Pro和p.Trp444Arg导致PC蛋白分泌障碍可能是遗传性PC缺陷症的分子致病机制。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wen MZ, Lu YF, Liu MN, et al. [Analysis of two cases of hereditary protein C deficiency causing venous thrombosis]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 40355354. doi:10.3760/cma.j.cn121090-20240628-00236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。